Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel H Wolf

Showing results (131-140 of 149) with videos related to

Pageof 15
Sort By:
Schizophrenia Bulletin Open|August 27, 2025
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Amy Shalev, Lu Liu, et al.
Schizophrenia Bulletin Open|August 27, 2025
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Lu Liu, Monica Chu, et al.
Human Brain Mapping|September 9, 2021
A meta-analysis of deep brain structural shape and asymmetry abnormalities in 2,833 individuals with schizophrenia compared with 3,929 healthy volunteers via the ENIGMA ConsortiumBoris A Gutman, Theo G M van Erp, Kathryn Alpert, et al.
Schizophrenia (Heidelberg, Germany)|October 15, 2025
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiativeZarina R Bilgrami, Eduardo Castro, Carla Agurto, et al.
Schizophrenia (Heidelberg, Germany)|April 3, 2025
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia ProgramJean Addington, Lu Liu, Amy Braun, et al.
Schizophrenia Bulletin|May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-SchizophreniaHenry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia (Heidelberg, Germany)|April 2, 2025
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia ProgramMichael P Harms, Kang-Ik K Cho, Alan Anticevic, et al.
Journal of Affective Disorders|January 26, 2026
Brain aging in bipolar disorder using a neuroimaging and machine learning-derived metric: Findings from the ENIGMA BD Working GroupHui Xin Ng, Christoph Abé, Martin Alda, et al.
Schizophrenia (Heidelberg, Germany)|March 25, 2025
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sampleKelly Allott, Walid Yassin, Luis Alameda, et al.
Molecular Psychiatry|January 15, 2026
Psychotropic medications and their interactions with subcortical brain volume in bipolar disorder: An ENIGMA mega-analysisSinead King, John O'Connor, Emma Corley, et al.
Pageof 15

Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
Schizophrenia Bulletin Open|August 27, 2025
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Amy Shalev, Lu Liu, et al.
Schizophrenia Bulletin Open|August 27, 2025
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Lu Liu, Monica Chu, et al.
Human Brain Mapping|September 9, 2021
A meta-analysis of deep brain structural shape and asymmetry abnormalities in 2,833 individuals with schizophrenia compared with 3,929 healthy volunteers via the ENIGMA ConsortiumBoris A Gutman, Theo G M van Erp, Kathryn Alpert, et al.
Schizophrenia (Heidelberg, Germany)|October 15, 2025
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiativeZarina R Bilgrami, Eduardo Castro, Carla Agurto, et al.
Schizophrenia (Heidelberg, Germany)|April 3, 2025
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia ProgramJean Addington, Lu Liu, Amy Braun, et al.
Schizophrenia Bulletin|May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-SchizophreniaHenry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia (Heidelberg, Germany)|April 2, 2025
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia ProgramMichael P Harms, Kang-Ik K Cho, Alan Anticevic, et al.
Journal of Affective Disorders|January 26, 2026
Brain aging in bipolar disorder using a neuroimaging and machine learning-derived metric: Findings from the ENIGMA BD Working GroupHui Xin Ng, Christoph Abé, Martin Alda, et al.
Schizophrenia (Heidelberg, Germany)|March 25, 2025
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sampleKelly Allott, Walid Yassin, Luis Alameda, et al.
Molecular Psychiatry|January 15, 2026
Psychotropic medications and their interactions with subcortical brain volume in bipolar disorder: An ENIGMA mega-analysisSinead King, John O'Connor, Emma Corley, et al.
Pageof 15